$1.61
0.06[3.87%]
At close: Apr 26
$1.61
0[0.00%]
After Hours: 5:32PM EDT
Bone Biologics
(NASDAQ:BBLG)Bone Biologics Stock (NASDAQ:BBLG), Analyst Ratings, Price Targets, Predictions
Bone Biologics Corp has a consensus price target of $2.25, established from looking at the 3 latest analyst ratings. The last 3 analyst ratings were released from EF Hutton, EF Hutton, and EF Hutton on April 13, 2023, April 3, 2023, and October 18, 2022. With an average price target of $2.25 between EF Hutton, EF Hutton, and EF Hutton, there's an implied 39.75% upside for Bone Biologics Corp from these 3 analyst ratings.
Analyst Firms Making Recommendations1
EF Hutton
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Bone Biologics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/13/2023 | BBLG | Buy Now | Bone Biologics | $1.61 | 39.75% | EF Hutton | Constantine Davides | → $540 | Reiterates | → Buy | Get Alert |
| 04/03/2023 | BBLG | Buy Now | Bone Biologics | $1.61 | 39.75% | EF Hutton | Constantine Davides | → $540 | Reiterates | → Buy | Get Alert |
| 10/18/2022 | BBLG | Buy Now | Bone Biologics | $1.61 | 39.75% | EF Hutton | Constantine Davides | → $540 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Bone Biologics (BBLG)?
The latest price target for Bone Biologics (NASDAQ: BBLG) was reported by EF Hutton on April 13, 2023. The analyst firm set a price target for $2.25 expecting BBLG to rise to within 12 months (a possible 39.75% upside). 0 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Bone Biologics (BBLG)?
The latest analyst rating for Bone Biologics (NASDAQ: BBLG) was provided by EF Hutton, and Bone Biologics reiterated their buy rating.
When was the last upgrade for Bone Biologics (BBLG)?
There is no last upgrade for Bone Biologics.
When was the last downgrade for Bone Biologics (BBLG)?
There is no last downgrade for Bone Biologics.
When is the next analyst rating going to be posted or updated for Bone Biologics (BBLG)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bone Biologics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bone Biologics was filed on April 13, 2023 so you should expect the next rating to be made available sometime around April 13, 2024.
Is the Analyst Rating Bone Biologics (BBLG) correct?
While ratings are subjective and will change, the latest Bone Biologics (BBLG) rating was a reiterated with a price target of $0.00 to $2.25. The current price Bone Biologics (BBLG) is trading at is $1.61, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.